Peptide-Labeled Near-Infrared Quantum Dots for Imaging Tumor Vasculature in Living Subjects

Department of Materials Science and Engineering , Stanford University, Palo Alto, California, United States
Nano Letters (Impact Factor: 13.59). 05/2006; 6(4):669-76. DOI: 10.1021/nl052405t
Source: PubMed


We report the in vivo targeting and imaging of tumor vasculature using arginine-glycine-aspartic acid (RGD) peptide-labeled quantum dots (QDs). Athymic nude mice bearing subcutaneous U87MG human glioblastoma tumors were administered QD705-RGD intravenously. The tumor fluorescence intensity reached maximum at 6 h postinjection with good contrast. The results reported here open up new perspectives for integrin-targeted near-infrared optical imaging and may aid in cancer detection and management including imaging-guided surgery.

24 Reads
  • Source
    • "In comparison with other dual-labeled NPs, IO-anti-EGFR-Cy5.5 NPs show excellent biocompatibility, satisfying colloidal stability, and enhanced MR contrast.24 Furthermore, Cy5.5, as one representative NIRF dye, possesses the minimum absorbance spectra in the NIR region,32 and enables characterization of deep diseased tissues.18 Dual-modality magnetic-fluorescent NP, which imparts contrast in both imaging modalities, such as the one described herein, can extend the prospects of MRI-fluorescence imaging, and facilitate information cross-validation and direct comparison between different modalities. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dual-modality imaging combines the complementary advantages of different modalities, and offers the prospect of improved preclinical research. The combination of fluorescence imaging and magnetic resonance imaging (MRI) provides cross-validated information and direct comparison between these modalities. Here, we report on the application of a novel tumor-targeted, dual-labeled nanoparticle (NP), utilizing iron oxide as the MRI contrast agent and near infrared (NIR) dye Cy5.5 as the fluorescent agent. Results of in vitro experiments verified the specificity of the NP to tumor cells. In vivo tumor targeting and uptake of the NPs in a mouse model were visualized by fluorescence and MR imaging collected at different time points. Quantitative analysis was carried out to evaluate the efficacy of MRI contrast enhancement. Furthermore, tomographic images were also acquired using both imaging modalities and cross-validated information of tumor location and size between these two modalities was revealed. The results demonstrate that the use of dual-labeled NPs can facilitate the dual-modal detection of tumors, information cross-validation, and direct comparison by combing fluorescence molecular tomography (FMT) and MRI.
    International Journal of Nanomedicine 01/2014; 9(1):33-41. DOI:10.2147/IJN.S52492 · 4.38 Impact Factor
  • Source
    • "QD in vivo imaging was previously reported based on QD-RGD targeting to integrin αvβ3 expressed in tumor angiogenic vessel endothelial cells only for glioblastoma xenografted in the front flank of nude mice.23,24 In this study, we established a HNSCC model by injecting human squamous cell carcinoma cell line BcaCD885 into the right cheek of nude mice. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Molecular imaging plays a key role in personalized medicine and tumor diagnosis. Quantum dots with near-infrared emission spectra demonstrate excellent tissue penetration and photostability, and have recently emerged as important tools for in vivo tumor imaging. Integrin αvβ3 has been shown to be highly and specifically expressed in endothelial cells of tumor angiogenic vessels in almost all types of tumors, and specifically binds to the peptide containing arginine-glycine-aspartic acid (RGD). In this study, we conjugated RGD with quantum dots with emission wavelength of 800 nm (QD800) to generate QD800-RGD, and used it via intravenous injection as a probe to image tumors in nude mice bearing head and neck squamous cell carcinoma (HNSCC). Twelve hours after the injection, the mice were still alive and were sacrificed to isolate tumors and ten major organs for ex vivo analysis to localize the probe in these tissues. The results showed that QD800-RGD was specifically targeted to integrin αvβ3 in vitro and in vivo, producing clear tumor fluorescence images after the intravenous injection. The tumor-to-background ratio and size of tumor image were highest within 6 hours of the injection and declined significantly at 9 hours after the injection, but there was still a clearly visible tumor image at 12 hours. The greatest amount of QD800-RGD was found in liver and spleen, followed by tumor and lung, and a weak fluorescence signal was seen in tibia. No detectable signal of QD800-RGD was found in brain, heart, kidney, testis, stomach, or intestine. Our study demonstrated that using integrin αvβ3 as target, it is possible to use intravenously injected QD800-RGD to generate high quality images of HNSCC, and the technique offers great potential in the diagnosis and personalized therapy for HNSCC.
    OncoTargets and Therapy 12/2013; 6:1779-1787. DOI:10.2147/OTT.S53901 · 2.31 Impact Factor
  • Source
    • "NPs with the fluorescence emitting properties have been used in cancer diagnostics. Different nanomaterials such as quantum dots (QDs) [10] [11], gold nanoparticles [12], silica nanoparticles [13] and nanocomposites [14] [15] have been employed for various biomedical applications. In addition to that, nanomaterials from carbon origin such as carbon nanotubes [16], graphene sheets [17] and nanodiamond [18] have also become promising candidates in cancer diagnostics and therapies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study demonstrates the effective synthesis of five different sized/shaped Pt NPs, within a narrow size regime of 1-21 nm using a modified methodology and the toxicity/biocompatibility of Pt NPs on Neuro 2A cancer cells was investigated elaborately by using light microscopic observations, tryphan blue exclusion assay, MTT assay and ICP-MS. The Pt NPs-C with sizes 5-6 nm showed superior non-cytotoxic property compared to the other four Pt NPs. These non-cytotoxic Pt NPs were employed for successful photothermal treatment of Neuro 2A cell lines using near-IR 1064 nm of laser irradiation. The Pt NPs-C could generate a 9 °C increase in temperature leading to effective photothermal killing of cancer cells. The MALDI-MS was used to prove the possibility of apoptosis related triggering of cell death in the presence of the Pt NPs. The results confirm that the current approach is an effective platform for in vivo treatment of neuro cancer cells.
    Biomaterials 04/2013; 34(23). DOI:10.1016/j.biomaterials.2013.03.077 · 8.56 Impact Factor
Show more

Preview (2 Sources)

24 Reads
Available from